Context Therapeutics Announces Fast Track Designation for CTIM-76 in Platinum-Resistant Ovarian Cancer Treatment

Context Therapeutics announced that CTIM-76 received FDA Fast Track Designation for treating platinum-resistant ovarian cancer. The designation highlights the potential of CTIM-76 to address unmet need for PROC patients. Context is currently evaluating CTIM-76 in a Phase 1 clinical trial, with interim data expected in June 2026. The FDA's Fast Track Designation aims to expedite the development and review of drugs with potential to treat serious conditions.